Amgen re-adjudicates Tavneos trial data after safety issues; unit ordered to pay $20.2M
AMGN sits 33% above its 52-week low of $267.83.
Summary
Amgen is re-adjudicating pivotal trial data for its drug Tavneos, and its Teneobio unit was ordered to pay $20.2 million for patent infringement. The Tavneos re-adjudication follows a series of negative news, including an FDA link to 76 cases in March and warnings and prescribing halts in Japan in May due to adverse events and deaths. This re-evaluation suggests Amgen is seriously reviewing the drug's profile in light of ongoing safety concerns and regulatory scrutiny, which could impact its future market access or sales. The $20.2 million patent infringement verdict is financially insignificant for Amgen's nearly $192 billion market cap. Amgen will review the re-adjudication results for regulatory discussions.
At the time of this announcement, AMGN was trading at $355.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $191.7B. The 52-week trading range was $267.83 to $391.29. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.